+44 (0)24 7671 8970
More publications     •     Advertise with us     •     Contact us
 
Loading...
News Article

Axithra raises €10m for biomedical application of photonics

News

Axithra, a new spin-off of imec and Ghent University, has announced a €10 million seed round, securing the first two years of R&D. Axithra develops a technology platform for therapeutic drug monitoring (TDM) to quickly and accurately measure drug concentrations in a patient’s blood.

The seed round led by imec.xpand and co-led by Kurma Partners amounted to €10 million, supported by an investor base including Qbic, Noshaq, White Fund, and Wallonie Entreprendre, as well as the companies Hamamatsu Photonics and Werfen Diagnostics.

For many drugs, the correct dosage is crucial to ensure the optimal effect. This is a constant focus in hospital units with seriously ill or debilitated patients, who often exhibit physiological changes over time, such as those in intensive care or oncology units. Insufficient doses mean a drug loses effectiveness, while excessive doses may cause toxic, potentially fatal, side effects. To address this challenge, Axithra will develop a therapeutic drug monitoring (TDM) platform based on optical technology. It aims at fast and accurate measurement of drug concentrations in blood, enabling timely adjustments of dosages as needed.

As a first application, the spin-off will deploy its technology to measure the concentration of beta-lactam antibiotics in a patient’s blood. This class of antibiotics is by far the most commonly used to treat or prevent bacterial infections and is administered to millions of intensive care patients each year. Axithra’s platform will ensure that treatments can be optimally tailored to the individual patient. Over time, other drug classes will be incorporated into the pipeline.

Prof. Jan De Waele, intensivist at Ghent University Hospital and president-elect of the European Society of Intensive Care Medicine, commented: “Given the large variation between patients in intensive care, this development will enable us to better treat our patients with severe infections, and protect them from possible harm. Because current solutions have long turnaround times, Axithra’s platform will help us to intervene more quickly, improving outcomes of severe infections and reducing the length of stay of patients in the intensive care unit, hereby decreasing costs.”

Axithra is an example of how processes developed for the semiconductor industry are now leveraged in the life sciences domain. Axithra combines imec’s semiconductor process knowledge with the photonics expertise of the Photonics Research Group, an associated imec lab at Ghent University. Prof. Roel Baets explained: “Our Raman-on-chip technology is the basis of Axithra’s solution. Raman spectroscopy is a commonly used technique for accurately identifying and quantifying molecules. Integration on a photonics chip makes this technique much more sensitive.”

Dr. Leander Van Neste, CEO of Axithra commented: “I am delighted with this broad, complementary investor base, including the regional and strategic support. I am convinced that together we can build out our TDM platform to be a true game-changer. Due to the simplicity and speed of our platform, we can customize medication for each individual patient, even with rapidly changing conditions, and in all sorts of environments, including outside the traditional hospital lab.”

Frank Bulens, partner at imec.xpand said: “Great to see such a broad investor support for this new spin-off from imec and UGent. This substantial seed round will allow the startup to achieve its prototype proof of concept milestone, a good basis for raising further financing to advance its product to the market.”

Alain Horvais, partner at Kurma Partners added: “We are confident that with a dynamic entrepreneurial team, Axithra will be able to provide physicians with a breakthrough TDM solution for a personalized and optimized patient treatment. Kurma Partners, through its specialized fund Kurma Diagnostics2, is pleased to support Leander and the Axithra team in this project.”

Axithra raises €10m for biomedical application of photonics
Vector Photonics and Sivers collaborate
PhotonVentures raises €60 million to supercharge photonics startups
Rockley completes human studies of blood pressure monitor
POET to demo 800G optical transceivers at CIOE 2023
Lightwave Logic expands its Colorado operations
Marvell announces new 800 Gbps coherent DSP
Lightelligence to Demonstrate Hummingbird Optical Network-on-Chip
Sandia Labs announces method to integrate microscale optical devices on silicon microchips
Israel-U.S. Binational Industrial R&D Foundation to invest $8 million in 9 new projects
Imec integrates thin-film photodiode into SWIR sensors
Advanced Micro Foundry and Ascenta Technologies launch MPW runs
Going Vertical to Advance PICs
Coherent has shipped over 200 billion VCSELs
Lightelligence Introduces Optical Interconnect for Composable Data Center Architectures
UK consortium to address skills shortages
Could silicon outperform GaAs in photodetectors?
POET samples 100G optical engines
Luceda Photonics and Aluvia Photonics release new process design platform
NTT achieves 300 GHz band transmission with beamforming
Automotive LiDAR market to reach $4.5B in 2028
Applied Materials and Fraunhofer IPMS launch metrology hub
InP-based lasers surpass 2.2 μm
PIC International 2023: The growth of silicon photonics continues
Automation: an essential tool for testing Photonic Integrated Circuits
Datacom will be the main driver for Silicon Photonics
KAIST research team unveils new path for dense photonic integration​
Component viability risks bursting the quantum bubble
How integrated photonics can transform the agrifood industry
SMART Photonics secures €100 million extra funding
MIT team grows arrays of perovskite nanoLEDs
Micro-transfer printing for heterogeneous PICs

×
Search the news archive

To close this popup you can press escape or click the close icon.
Logo
×
Logo
×
Register - Step 1

You may choose to subscribe to the PIC Magazine, the PIC Newsletter, or both. You may also request additional information if required, before submitting your application.


Please subscribe me to:

 

You chose the industry type of "Other"

Please enter the industry that you work in:
Please enter the industry that you work in: